日本人再発性多発性骨髄腫患者におけるアフレセルチブ単剤療法の研究

基本情報

NCT ID

NCT02177682

ステータス

中止

試験のフェーズ

第1相

試験タイプ

介入

目標被験者数

9

治験依頼者名

Novartis

概要

Afuresertib, an AKT inhibitor, has shown in vitro and in vivo activity in multiple myeloma models. AKT inhibitor has also demonstrated encouraging clinical activity in multiple myeloma. This study is designed to determine the tolerability, safety, pharmacokinetics and efficacy of afuresertib as monotherapy in Japanese relapsed multiple myeloma patients. This is an open label, dose-escalating, phase I study. Afuresertib will be given daily until the subjects meet any study treatment withdrawal criteria including disease progression. A total of up to 24 subjects will be enrolled in the study.

対象疾患

介入

依頼者（Sponsor）